Propellon Therapeutics Inc. (Triphase Accelerator)

oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
Developing potent and selective small molecule WDR5 inhibitors for the treatment of leukemias and solid tumours

Related news

FACIT Announces Investment in Propellon Therapeutics

Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers. Read More

Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers

The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships. Read More

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy

Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia. Read More

FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia

FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.